Schrodinger announces expanded software agreement with Eli Lilly

Schrodinger (SDGR) earlier provided an update on its progress across the business and announced its development and operational goals for 2024. Schrodinger announced an expanded, three-year, software agreement with Eli Lilly and Company (LLY). The three-year agreement builds on the collaboration established in 2022. The agreement provides Lilly with large-scale access to Schrodinger’s full suite of technologies to enable and accelerate all stages of drug discovery, from target enablement and assessment of target druggability to hit discovery and lead optimization activities through development candidate identification. Schrodinger will provide advanced support to ensure full integration and optimization of the platform across Lilly’s research sites. Schrodinger highlighted several 2023 achievements: Presented initial results from the healthy volunteer study of SGR-1505, its MALT1 inhibitor; Advanced the Phase 1 study of SGR-1505 in patients with advanced B-cell malignancies, including expanding the study at additional sites in the U.S. and Europe; Received FDA orphan drug designation for SGR-1505 in mantle cell lymphoma; Received IND clearance for SGR-2921, its CDC7 inhibitor, and initiated a Phase 1 study in patients with AML and MDS. Schrodinger outlined the following development and operational goals for 2024: Advance the Phase 1 study of SGR-1505 in advanced B cell malignancies to enable initial data release in late 2024 or 2025; Advance the Phase 1 study of SGR-2921 in patients with AML/MDS to enable initial data release in late 2024 or 2025; Submit the IND application for SGR-3515 in the first half of 2024 and initiate a Phase 1 study in 2024; Advance the discovery-stage proprietary pipeline to enable an additional IND submission in 2025.